Copyright
©The Author(s) 2016.
World J Gastroenterol. Nov 21, 2016; 22(43): 9613-9622
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9613
Table 5 Relapse by treatment modifications and hepatitis C virus genotype (n = 283) n (%)
| Relapse Yes | Relapse No | P value | |
| (n = 49) | (n = 234) | ||
| Dose reduction | |||
| Any dose reduction | 10 (19.2) | 42 (80.8) | 0.686 |
| Peg-IFN only | 0 (0) | 9 (100) | 0.163 |
| Ribavirin only | 4 (26.7) | 11 (73.3) | 0.325 |
| Both peg-IFN and ribavirin | 6 (21.4) | 22 (78.6) | 0.544 |
| Genotype | |||
| 1 | 14 (25.0) | 42 (75.0) | 0.279 |
| 2 | 0 (0) | 4 (100) | |
| 3 | 21 (14.7) | 122 (85.3) | |
| 6 | 14 (17.5) | 66 (82.5) |
- Citation: Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622
- URL: https://www.wjgnet.com/1007-9327/full/v22/i43/9613.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i43.9613